A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab (Anti‐CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma
Pharmacology, Toxicology and Pharmaceutical Science
1
3%
Agricultural and Biological Sciences
1
3%
Other
0
0%
Unknown
19
61%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2020.
All research outputs
#20,612,116
of 23,201,298 outputs
Outputs from American Journal of Hematology
#3,086
of 3,386 outputs
Outputs of similar age
#320,750
of 375,336 outputs
Outputs of similar age from American Journal of Hematology
#68
of 78 outputs
Altmetric has tracked 23,201,298 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,386 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 375,336 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
